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Abstract 
High mobility group box 1 (HMGB1) is a mobile chromatin protein that can relocate into 
the external environment and act as a cytokine. HMGB1 cellular release can be passive, by 
cell necrosis, or active, by living cells after a specific stimulus is received. 
HMGB1 does not possess a leader sequence, a sequence usually present at the N-
terminus of secreted proteins that is sufficient to address them through the ER/Golgi exocytic 
pathway. This work focused on the molecular mechanism by which HMGB1, as a leaderless 
protein, can be actively exocytosed by living cells. 
HMGB1 undergoes post-translational modifications that allow it to move to various 
cellular SUb-compartments: 
1) Translocation from the nucleus to the cytosol 
2) Loading inside exocytic vesicles (secretory Iysosomes) 
3) Release into the extracellular milieu by vesicle degranulation. 
The post-translational modification involved in the first translocation step was already known 
to be lysine acetylation. Here I demonstrate the necessity of cysteine glutathionylation for the 
translocation inside secretory Iysosomes, and the direct involvement of Multidrug Resistance 
Proteins (MRP/ABCC) in the transport process. 
I started with the observation that HMGB1 and IL-1 beta, another leaderless cytokine, 
do colocalize inside secretory Iysosomes in macrophages, and that a pharmacological 
inhibitor of IL-1beta exocytosis, glybenclamide, inhibits HMGB1 release too. Glybenclamide 
is a general inhibitor of the ABC transporter Superfamily, a large family of transmembrane 
proteins that transport ions, drugs and small peptides. Based on the sensitivity or insensitivity 
to different drugs, the HMGB1 transporter was likely to belong to ABC C group. 
Overexpression of MRP1/ABCC1, MRP2/ABCC2 and MRP3/ABCC3 endows activated 
cells with the ability to secrete HMGB 1. Moreover, macrophages from Mrp1-1- mice have 
impaired HMGB1 exocytosis. I also suggest that HMGB1 is unfolded during its translocation. 
MRP transporters are known to recognize glutathionylated substrates. Indeed, HMGB1 
can be glutathionylated, and depletion of the glutathione intracellular pool impairs HMGB1 
secretion. 
MRP transporters can be overexpressed in drug resistant tumour cells, where they 
pump chemotherapeutic agents out of the cell. I suggest that cells that are drug-resistant 
because of MRP1 overexpression might also secrete HMGB1. 
VII 
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Introduction 
HMG proteins (High Mobility Group Box) and HMGB1 
The HMG proteins, so-called for 'high mobility group', are perhaps the most extensively 
studied non-histone chromosomal proteins. They comprise 3 families: 
1) HMGB (HMGB1/2) family with molecular mass of about 25 kDa 
2) HMGN (HMGB14/17) family with molecular mass of about 10 kDa 
3) HMGA (HMG-lfYIC» family with molecular mass of about 15 kDa 
HMGB proteins in mammalians comprise HMGB 1, HMGB2 and HMGB3. The structure 
of these proteins in highly conserved (more than 80% amino acid sequence identity), and 
their biochemical properties are so far indistinguishable. HMGBs are composed of 3 different 
domains: two homologous DNA binding domains, HMG-box A and HMG-box B, which are 
each around 75 amino acids long, and the C-terminus domain which is highly negatively 
charged and consists of a stretch of glutamate and aspartate residues. The acidic tail 
modulates DNA binding properties of HMGB1 (Knapp et al 2004). and is shorter in HMGB2 
and shortest in HMGB3. The main ability of HMG-boxes is to bind DNA in the minor groove 
and produce distortions in the double helix. 
Putative counterparts of mammalian HMGBs are present in: 
S. cerevisiae (non-histone proteins 6A and 6B. NHP6A and NHP6B) 
D. melanogaster (HMG-D and HMG-Z) 
all vertebrates. including X. levis (x-HMG) and zebrafish (6 proteins). 
Single HMG-box domains, with no acidic tail. are characteristic of transcription factors like 
SRY (sex-determining region V), SOX (SRY-related HMG-box) and LEF-1 (lymphocyte 
enhancer factor 1), the nucleolar transcription factor UBF (upstream binding factor), the 
lymphoid transcription factors TCF1 (T-cell factor 1) and the yeast mating genes mat-Me and 
MATa1 (Bustin et al 2002; Thomas and Travers 2001). 
HMGB1 protein 
The non-histone nuclear-binding protein high-mobility group box 1 protein (HMGB 1), is 
encoded on human chromosome 13q12-13. It is a small protein, approximately 28 kDa, and 
is an abundant component of all mammalian nuclei. 
The entire human HMGB1 cDNA was sequenced by Wen (1989), from a human 
placenta cDNA library. Northern blot analysis showed that 3 mRNA species of approximately 
1.0, 1.4, and 2.4 Kb were expressed in all mammalian organs and cell lines examined. 
Introduction 
As mentioned before, the protein is able to bind with high affinity to specific DNA 
structures and bend them, but does not show nucleotide sequence preference (Bianchi et al 
1989). In the beginning, HMGB1 was considered and studied for its chromatin binding 
capability and as a chromatin structural protein. HMGB 1, in the nucleus, interacts with the 
DNA minor groove and several nuclear transcription factors, acting as a transcriptional 
chaperone. Later it was found that, when it is present in the cell extemal environment, 
HMGB1 behaves in a cytokine-like fashion (Wang et aI1999). 
The amino acidic stretch displays 2 nuclear localization signals (NLS1 and NLS2) but no 
secretion leader sequence is present. Moreover, HMGB1 contains several acetylatable lysine 
residues, as depicted in figure 1 (Muller et al 2001, Lotze and Tracey 2005). 
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1) Linear diagram of HMGB1 (Lotze and Tracey 2005) The diagram indudes the residues that constitute the A-
box (pink), B-box (purple) and acidic tail (green). HMGB1 also contains 43 lysine residues, some of which are 
frequently acetylated in lipopolysaccharide-activated macrophages (shown in bold). These lysine residues are 
found within two nudear-Iocalization signals (indicated by dashed boxes): NLS1 , which spans amino acids 28-44; 
and NLS2, which spans amino acids 179-185. The acidic carboxyl terminus contains two amino acids that differ 
between mice and humans (indicated by arrows). This acidic region is thought to interact with and protect the A-
box and B-box during emigration from the nudeus. 
HMGB 1 is passively released from necrotic cells and actively secreted by activated 
myeloid cells and tumour cells. As a cytokine, HMGB1 activates endothelial cells, promotes 
2 
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angiogenesis, enhances haematopoietic stem-cell migration and drives inflammation 
(Oegryse et al 2001 , Schlueter et al 2005). HMGB1 endothelial stimulation leads to 
enhanced expression of adhesion molecules, including intercellular adhesion molecule 1, 
vascular cell-adhesion molecule 1, and RAGE (receptor for advanced glycation end-
products), see figure 2 (Lotze and Tracey 2005). 
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2) Intranuclear and extranuclear roles of HMGB1 (Lotze and Tracey 2005) 
• Irducu cat miQr&tbn end 
tumW>rf~N metaotaal. 
A. HMGB1 in the nudeus interacts with the nudear matrix, chromatin and transcription factors; it functions as a 
transcriptional chaperone. 
B. HMGB1 present at the cell surface promotes axonal sprouting and neurite outgrowth. Membrane-bound 
HMGB1 also promotes cell migration and tumour metastasis. 
C. In the extracellular fluid, HMGB1 signals through RAGE (receptor for advanced glycation endproducts), and 
possibly through Toll-like receptor 2 (TLR2) and TLR4, 
D. HMGB 1 can be secreted by activated macrophages and dendritic cells, after activation by bacterial products, 
such as endotoxin, or pro-inflammatory cytokines 
The secretion pathway involves nudeus-cytosol translocation of hyperacetylated HMGB1 , loading in secretory 
Iysosomes, fusion with the cell membrane and release into the extracellular milieu . 
E. Necrotic cell release HMGB1 is by not the tightly bound histones. 
F. During apoptoSls HMGB1 is sequestered by the chromatin. 
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In 1999 Wang first identified HMGB 1 as a potential late mediator of lethality due to 
bacterial endotoxin (LPS). HMGB1 protein was found to be released by cultured 
macrophages more than 8 hours after stimulation with LPS, TNF-alpha or IL-1 beta. Mice 
showed increased HMGB1 serum levels after the treatment. Administration of antibodies 
against HMGB1 attenuated LPS lethality, and administration of HMGB1 itself was lethal 
(figure 3). 
Wang also studied HMGB1 release in human serum, and he observed that in normal 
patients the protein was not detectable, but significant levels were observed in patients with 
critical septicaemia. HMGB1 levels were higher in patients that died, if compared with 
patients that displayed non lethal infections. (Wang et al 1999; Lotze and Tracey 2005). 
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3) HMGB1 and sepsis (Wang et aI1999) 
A. Release of HMGB1 from cultured macrophages after stimulation with LPS 
Murine macrophage-like RAW 264.7 cells were treated with LPS (100 nglml) and proteins in the cell-conditioned 
medium were analysed by western blotting with anti-HMGB1. 
B. Accumulation of HMGB1 in serum of lPS-treated mice 
Male Balb/C mice (20 to 23 g) were treated intra peritoneally (ip) with 10 mg/kg LPS,. Serum was assayed for 
HMGB1 by western blotting. 
C. Anti-HMGB1 antibodies protect against LPS lethality in mice 
Male Balb/C mice (20 to 23 g) were randomly grouped (10 mice per group) and treated with LPS at LD100 
(25 mglkg). Anti-HMGB1 (Ab) or preimmune serum (0.2 ml per mouse, ip) was administered 30 min before LPS. 
Additional doses of preimmune (0.4 ml, ip) or anti-HMGB 1 (0.4 ml, ip) were administered at 12 and 36 hours after 
LPS as indicated. 
D. Delayed administration of anti-HMGB1 protects against lPS lethality in mice 
Male Balb/C mice (20 to 23 g) were randomly grouped (seven mice per group) and treated with LPS at LD100 of. 
Anti-HMGB1 or preimmune serum (0.4 ml per mouse) was administered at 2,24, and 36 hours after LPS. 
E. Administration of rHMGB1 is lethal to mice 
Male Balb/C mice (20 to 23, 10 animals per group) were injected with a non lethal dose of LPS (3.1 mg/kg, ip). 
Purified rHMGB1 protein was administered intraperitoneally in the doses indicated at 2, 16, 28, and 40 hours after 
LPS. 
In 2004 Yang et al reported that, in a murine sepsis model of surgically induced 
peritonitis, HMGB1 serum levels are significantly increased. Specific inhibition of HMGB1 
activity, by antibodies against HMGB1 or HMGB1 DNA-binding A box, significantly increased 
mice survival. Animals pre-treated with either HMGB1 antagonist were protected against the 
development of sepsis-induced multi-organ injury. These observations demonstrated that the 
specific inhibition of endogenous HMGB 1 therapeutically reverses the lethality of induced 
sepsis. 
Interestingly, in 2002 Zetterstrom identified HMGB1 as an antibacterial factor 
produced and stored intracellularly in human adenoid glands. 
HMGB1 receptors 
A great deal of evidence indicates RAGE (Receptor for Advanced Glycation Endproducts) as 
HMGB1 cell surface receptor. Therefore, colocalization of RAGE and HMGB1 on the leading 
edge of advancing neurites and glioma cells, indicates their potential contribution to cellular 
migration and tumour invasion (Parkkinen et al 1993, Lotze and Tracey 2005). 
In 2000 Taguchi demonstrated that blockage of RAGE/HMGB1 interaction decreases 
growth and metastases of both implanted tumours and tumours developing spontaneously in 
susceptible mice. Inhibition of the RAGE/HMGB 1 interaction suppressed activation of p44 
1p42, p38, and SAP/JNK MAP kinases, and expression of matrix metalloproteinases. 
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4) RAGE is not the unique HMGB1 receptor (Kokkola et aI2004) 
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HMGB1 induces mitogen-activated protein (MAP) kinase phosphorylation in RAGE-/- and IL-1RI-/- mouse 
macrophages (Mf). Mf derived from RAGE-/- and IL-1R-/- mouse bone marrow were stimulated with HMGB1 
(10 mg/ml) or medium alone (control) and the phosphorylation of p38 MAPK, p44/42 MAPK and SAPKlJNK was 
recorded after 30 min by western blotting using antibodies against the phosphorylated forms of MAP kinases. The 
grade of phosphorylation is expressed as net intensity. 
Kokkola in 2004 reported that macrophages from RAGE-/- mice produce significantly 
lower amounts of TNF, IL-1 band IL-6, while IL-1 RI-/- and TLR2-/- macrophages produce 
cytokine levels comparable with wt controls in response to HMGB1 stimulation. Kokkola 
concluded that HMGB 1 has the potential to induce a pro-inflammatory phenotype by acting 
mainly throughout RAGE, but other minor receptors and transduction pathway must exist 
(Figure 4). 
Phenotype of HMGB1- and HMGB2-deficient mice 
Calogero et al (1999) generated Hmgb1 conventional KO mice. Hmgb1-/- pups are born 
alive, but die within 24 hours because of hypoglycaemia. 
6 
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5) Hmgb1-1- mice develop neonatal hypoglycaemia (Calogero et al 1999) 
A. Hmgb1-1- mice die within the first day of life but can survive if given glucose parenterally. Intraperitoneal 
glucose injections were administered to 10 Hmgbrl- newborns during the first days after birth. Survival is 
indicated by a blue line. Ten Hmgbrl- control mice, injected with saline solution, all died within day 1 (red line), 
similar to untreated Hmgbrl- mice. 
B. Periodic add-Schiff (PAS) staining for glycogen (magenta) in livers from Hmgbrl- mice are shown. Despite 
very low blood glucose concentrations, hepatocytes of Hmgb1-1- mice do not completely mobilize glycogen 
(arrows, glycogen granules). 
C. Phenotype of an Hmgb1-1- spontaneous survivor at day 25. Spontaneous survivors of the mixed 129Sv/CD1 
genetic background are very similar to the most successfully glucose-rescued Hmgb1-1- mice of 129Sv/BALB-c 
background: they have a very reduced size, but respond positively to basic neurological tests. All spontaneous or 
glucose-treated surviving animals have sealed eyelids, arched backs, long hind paws and abnormal gait. 
D. The absence of Hmgb1 reduces the activity of GR in transfection assays. The expression of a GR-controlled 
reporter is reduced in Hmgbrl- fibroblast cell lines exposed to dexamethasone. 
Hmgb1 KG mice survive for several days, if glucose solution is injected intra-
peritoneally, then waste away with pleiotropic defects (with no alteration in the immune 
repertoire) (Figure SA, C). 
It was observed that a high glycogen level is present in the liver (figure 5B) but is not 
metabolized. Cell lines lacking Hmgb1 grew normally, but the gene expression controlled by 
7 
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the glucocorticoid receptor (GR) is impaired (figure 50). Calogero et al concluded that 
Hmgb1 is not essential for the overall organization of chromatin in the cell nucleus, but is 
critical for proper transcriptional control by specific transcription factors. 
Ronfani et al (2001) generated Hmgb2-/- mice; these were healthy but males 
had reduced fertility. This phenotype was due to an increased apoptosis level (Figure 
6) in seminiferous tubules, resulting in a diminished production of spermatozoa. 
HMGB2 protein does not seem to be essential, perhaps HMGB1 has a redundant 
function. 
6) Abnormalities in the testis of HmgbZ"l- mice (Ronfani et al 2001) 
A. B. Electron micrographs of an elongated spermatid where the acrosome (arrows) is detached from 
the nucleus, impairing its function. 
C. D. TUNEL staining for apoptotic cells in testis seminiferous tubules of Hmgb71- mice, showing the 
high content of dead cells. 
E. F. Haematoxytin-eosin stained sections of testis from a 163-day Hmgb71- mouse. The regular 
periphery-ta-Iumen succession of spermatogonia, primary and secondary spermatocytes, spermatids 
and spermatozoa is lost, cells are separated by gaps, and degenerated Sertoli cells with large 
vacuoles are present. 
8 
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HMGB1 nucleus to cytosol translocation and extracellular release 
LPS is a trigger that initiates the cellular biochemical modifications that drive HMGB1 
secretion. HMGB1 at first exits the nucleus (Bonaldi et al 2003), then enters the secretory 
vesicles (Gardella et al 2002) and finally reaches the external milieu. 
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7) HMGB1 acetylation and nucleus-cytosol translocation (Bonaldi et al 2003) 
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A. HMGB1 moves to the cytoplasm following TSA treatment Exposure of mouse fibroblasts to 10 ng/ml TSA 
for 1 h causes a significant relocation of HMGB1-GFP to the cytoplasm; no vesides are recognizable. The 
mutation of six Iysines to arginines (2XKKK-+RRR) prevents the cytoplasmic accumulation of HMGB1-GFP, even 
after TSA treatment. 
B. HMGB1 is multiply acetytated in activated monocytes LPS-activated human monocytes hyperacetylate 
HMGB1 and accumulate it in cytoplasmic vesicles. Macropaghes purified from peripheral blood were cultured 
overnight, with or without LPS. HMGB1 is nudear in unstimulated macrophages, as opposed to nuclear plus 
vesicular in LPS-activated macrophages. A1iquots of untreated and LPS-activated macrophages were freeze-
thawed , and about 400 I1g of total protein extract was loaded onto 2D gels, blotted and immunodetected with anti-
HMGB 1. Note the major additional HMGB 1 spot in activated macrophages. 
C. The control of HMGB1 secretion in professional inflammatory cells In all cells, induding resting 
inflammatory cells, HMGB1 shuttles between nudeus and cytoplasm; nudear import is active, and the protein 
migrates back to the cytoplasm via passive diffusion and CRM1-mediated active export. When HMGB1 is 
underacetylated (after TSA treatment), the rate of nudear import exceeds that of rediffusion plus export, and the 
protein appears predominantly or solely nudear. Upon activation of inflammatory cells through binding of IL-1 ~ I 
TNF , LPS or HMGB1 itself to their own receptors, the NF-KB and MAP kinase (MAPK) pathways are activated. 
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Phosphorylated MAPKs migrate to the nudeus, where directly or via adaptor proteins they activate histone 
acetylases or inhibit deacetylases. This in turn promotes acetylation of HMGB1. Exported acetyl-HMGB1 cannot 
return to the nudeus. Myeloid cells are equipped with secretory Iysosomes, a variety of Iysosomes that can be 
secreted upon appropriate stimulation and that can accumulate IL-1 ~ or HMGB1, presumably through specific 
transporters embedded in the lysosomal membrane. Upon binding of LPC (an inflammatory lipid) to its own 
receptor, the secretory Iysosomes carrying HMGB1 fuse with the plasma membrane and secrete their cargo. 
The process of HMGB 1 exocytosis by macrophages during the inflammatory burst can 
be subdivided in three fundamental steps: 
1) Translocation of HMGB 1 from the nucleus to the cytosol 
2) Charging of HMGB1 inside cytoplasmic organelles (secretory Iysosomes) 
3) Fusion of containing HMGB1 organelles with the plasma membrane and 
subsequent release of HMGB1 in the external milieu. 
a) The first step was investigated in detail by Bonaldi et al in 2003. 
The pattem of 2D-PAGE electrophoretic mobility of modified HMGB1 from macrophagic cells 
(Figure 7) is compatible with multiple lysine acetylation. Moreover, a deacetylase inhibitor, 
trichostatin A (TSA), causes the relocalization of a fraction of HMGB1 from the nucleus to the 
cytoplasm. Mutation of six Iysines to glutamine, which mimic acetylated lysine due to the 
absence of positive charges, also causes the relocalization of a fraction of HMGB 1 from the 
nucleus to the cytoplasm. Mutation of the same six Iysines to arginine (which cannot be 
acetylated) makes HMGB1 localization unresponsive to deacetylase inhibitors (Figure 7). 
b) The second exocytosis step is the point under investigation in my work. 
HMGB 1 utilizes an active transporter to be internalized inside vesicles. Gardella in 2002 
found that monocytes/macrophages LPS stimulate release of both, HMGB1 and IL-1 beta and 
that these two cytokines partially co-localize inside a secretory-competent Iysosomes-type 
organelle, the "secretory Iysosomes". 
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8) Il-1 beta and HMGB1 co-localize with chathepsln 0 (Gardella et al 2002) Double immunogold labeling of 
HMGB1 and cathepsin D (A and B) and HMGB1 and IL-1beta (C and E). Arrows point to small gold particles 
(HMGB1). and arrowheads point to large gold particles (cathepsin D in A and B. IL-1beta in C and E). 
(Figure 8). Secretory Iysosomes are a special class of Iysosomes, which are present almost 
exclusively in hemopoietic cells, in keeping with their major role in immune and inflammatory 
response (Blott and Griffiths 2002). 
In spite of its presence inside secretory organelles, HMGB 1 lacks a signal peptide that 
would direct it to the exocytotic pathway via Endoplasmatic Reticulum and Golgi apparatus. 
The absence of this signal is shared with a small number of other secreted proteins, called 
leaderless proteins, one of which is IL-1 beta. 
My thesis work begins at this point. I wanted to understand how HMGB1 can traverse 
the membrane of secretory Iysosomes and accumulate inside them. 
c) The third step, lysosome degranulation, needs second signal(s), necessary to trigger the 
fusion of secretory Iysosomes with the cellular membrane. 
Lysosome degranulation can be stimulated by ATP and Iysophosphatidylcholine (LPC), 
respectively, thought activation of two receptors, the purinergic receptor P2X7 and the G-
protein coupled receptor G2A (Andrei et al 2004; MacKenzie et al 2001). 
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HMGB1 passive release 
In 2002 Scaffidi et al demonstrated that HMGB1 passive release, can serve as a diffusible 
signal of unprogrammed death, which can be used as a cue to nearby cells. Necrotic 
embryonic fibroblasts from Hmgb1-1- mice display a greatly reduced ability to promote 
inflammation, which indicates that HMGB1 release can signal cellular damage to 
neighbouring cells. Apoptotic cells do not release HMGB1; the protein remains anchored to 
chromatin even after secondary necrosis and autolysis, and cannot promote inflammation 
even if apoptotic cells are not cleared by phagocytic cells (Figure 10). Apoptotic cells are not 
the result of a present an immediate insult and do not trigger inflammation in physiological 
conditions. The way in which apoptotic chromatin binds HMGB1 is still unknown. 
Core histones, although more abundant than HMGB1, would probably not be good signals of 
necrosis, as they remain anchored to the insoluble chromatin of necrotic cells. 
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10) HMGB1 is associated to the chromatin of living and apoptotic but not necrotic cells (Scaffidi et al 2002) 
Both the medium bathing the cells (S) and the cells (P) were analysed by SOS-PAGE. Histones were visualized 
by Coomassie blue staining, HMGB1 by immunoblotting or immunostaining with antibody to HMGB1, DNA by 
OAPI. 
A. Living cells expressing HMGB1-GFP. imaged by differential interference contrast and in green fluorescence. 
B. Necrotic cells with no permeabilization. The amount of HMGB1 in the medium was proportional to the number 
of necrotic cells (about 50%). 
C. Apoptotic cells with permeabilization . 
Leaderless proteins 
Secreted soluble proteins typically possess an N-terminal signal (leader sequence) that is 
able to address the na'ive protein inside ER during ribosomal mediated translation. Secreted 
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proteins follow a vesicular transport via the Golgi apparatus to the cell surface (Figure 11); 
this exocytosls pathway is known as the classical ERlGoigi dependent secretory pathway 
(Rubartelili and Sitia 1991). 
In the past 10 years a small set of proteins have been identified that are released in the 
external environment of the cells but that do not possess leader sequences (Figure 11). The 
leaderless secreted proteins described up to now are: 
CNTF (Ciliary Neurotrophic Factor) 
Coagulation factor XIII, alpha chain 
Beta-galactoside-binding protein 
EMAP II (Endothelial/monocyte activating polypeptide II) 
FGF1 (Fibroblast Growth factor 1) 
FGF2 (Fibroblast Growth factor 2) 
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11) Cargo proteins and potential export routes of leaderless and classical protein secretion (Nickel 2005) 
Non dassical mechamsm' 1) endosomal recyding 2) plasmamembrane transporter 3) flippaseslfloppases 
4 )Blebbing. 
Classical mechanism: ERlGoigi route. 
Glia activating factor (FGF9) 
HME2 (Homeobox protein engrailed-2) 
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IL 1 beta (Interleukin 1 beta) 
IL 18 (lnterleukin 18) 
IL-1 RA (IL-1 receptor antagonist) 
LEG3 (Galectin-3) 
Mammary-derived growth inhibitor 
MIF (Macrophage migration inhibitory factor) 
Prothymosin 
PD-ECGF (Platelet-derived endothelial cell growth factor) 
THIO (Thioredoxin) 
THTR (Thiosulfate sulfurtransferase) 
Tat (HIV1) 
ICE (Caspase 1/1L-1 beta converting enzyme) 
Annexin 1 
Introduction 
As reviewed by Nickel 2005, at least four different models of non classical export can 
exist. IL-1beta, En2 and HMGB1 export involves import into intracellular vesicles, which are 
probably endosomal subcompartments (secretory Iysosomes). FGF-1 and FGF-2 probably 
reach the extracellular space by direct translocation across the plasma membrane, but they 
apparently use distinct transport systems. The Leishmania cell surface protein HASPB also 
translocates directly across the plasma membrane and requires that the protein be 
membrane-anchored through dual acylation at the N-terminus. Therefore, a flip-flop 
mechanism is required to translocate the protein in the outer layer of the plasma membrane. 
The final postulated pathway of unconventional protein secretion involves the formation of 
exosomes, vesicles that form on the outer surface of the cell in a process known as 
membrane blebbing. Exosomes are labile structures that release their contents into the 
extracellular space. It has been suggested that this pathway may be used by the galectins 
(Figure 11). 
Interleukin-1 beta 
Interleukin-1 beta (IL-1 beta) belongs to the Interleukin-1 family, which has three other 
members: IL-1 alpha, IL-1 receptor antagonist and IL-18. 
Interleukin-1 proteins are involved in the inflammatory response, and are the 
endogenous pyrogens which stimulate the release of prostaglandin and collagenase from 
synovial cells. IL-1 biological activity is extracellular but the protein lacks the secretory signal 
sequence (Rubartelli et al 1990). 
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In mammals IL-1 beta is produced in response to many stimuli which include LPS, numerous 
microbial products, cytokines (TNF, INFy, GM-CSF and IL-2), T-cel//antigen presenting cell 
interactions and Immune complexes (Stylianou and Saklatvala 1998). 
IL-1 beta , after macrophage stimulation by LPS, is contained inside secretory 
Iysosomes (Hamon et al 1997). IL-1 beta is synthesized by monocytes/macrophages as a 35 
kDa precursor which accumUlates in the cytOsol (Singer et al 1988). Caspase-1l1nterleukin 
Converting Enzyme (ICE) then processes pro-IL-1 beta into the mature form of about 17 kDa. 
ICE is present in the cytosol as a p45 inactive prozyme, the ICE active form is p10/p20 
(Figure 12) (Singer et al 1995; Ayala et al 1994). IL-1 beta maturation takes place in the 
secretory Iysosomes (Andrei et al 1999) where both IL-1 beta and active ICE co-localize. A 
general ABC transporters inhibitor, glybenclamide, inhibits IL-1 beta vesicle loading (Hamon 
et al 1997). possibly by inhibiting the transporter ABCA 1. 
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12) IL-1beta exocytosis model Pro-lL-1beta is present in the cytosol and is loaded inside the secretory 
Iysosomes by the activity of a glybenclamide sensitive ABC transporter (ABCA 1). 
ABC transporters superfamily 
The ~ TmJ~fndingJCassette (ABC) transporter superfamily is composed of a set of 
transmembrane proteins that translocate compounds across plasma and intracellular 
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membranes. The name ABC transporters was first introduced by Higgins (1992), who cloned 
and sequenced the first ABC transporter, the histidine permease (Higgins et al 1982). 
All human and mouse ABC genes have standard nomenclature, developed by the 
Human Genome Organization (HUGO). Details of the nomenclature scheme can be found at: 
http://www.gene.ucl.ac.uklnomenclature/genefamily/abc.html. 
In summary the ABC transporter superfamily is organized in seven sub-branches: 
1) Subfamily A (ABCA) - ABC1 
2) Subfamily B (ABCB) - MDRITAP 
3) Subfamily C (ABCC) - CFTRlMRP 
4) Subfamily D (ABCD) - ALD 
5) Subfamily E (ABCE) - OABP 
6) Subfamily F (ABCF) - GCN20 
7) Subfamily G (ABCG) - WHITE 
Mutations in some of the ABC transporter genes are the cause of a variety of human 
diseases with Mendelian or complex inheritance; in fact, many of these genes were originally 
identified by positional cloning of human disease genes: 
Tangier disease (ABCA1) 
Immune deficiency (ABCB2-3ITAP1-2) 
Progressive familial intrahepatic cholestasis (ABCB4) 
X-linked sideroblastic anemia and ataxia (ABCB7) 
Dublin-Johnson syndrome (ABCC2) 
Pseudoxantoma elasticum (ABCC6) 
Cystic Fibrosis (ABCC7/CFTR), 
Familial persistent hyperinsulinemic hypoglycemia of infancy (ABCC8) 
adrenoleukodystrophy (ABCD1 ) 
Sitosterolemia (ABCG5/8) 
ABC transporters perform translocation of different toxic compounds, drugs, ions, peptides, 
lipids or bile salts, across the hydrophobic bilayer of the plasma membrane, often against 
concentration gradients. The translocation process consumes energy that is obtained from 
A TP hydrolysis. 
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ABC transporter structure 
ABC transporters are typically composed of 4 domains (as depicted in figure 13, Higgins and 
linton 2004), two transmembrane domains (TMD) formed by several hydrophobic alpha-
helices and two Nucleotide Binding Folds (NBF). The four domains can be encoded by two 
different polypeptides which can dimerise, or can be fused into a single protein. 
The ABC transporters were classified on the basis of the sequence of their ATP-binding 
domains, the NBF. The NBF displays a typical and conserved structure: it is composed of 
two Walker domains, A and B, separated by the C signature. 
13) Typical ABC transporter structure (E. coli BtuCD homologue of mammalian ABC transporter) ( Higgins 
and LInton 2004) In yellow and orange TMDs, in purple and cyan NBFs. TMDs are composed by several 
hydrophobic alpha helices spanning the membrane. NBFs are alpha/beta Rossmann folds. 
ABC transporters are large membrane proteins and for this reason it is difficult to 
crystallize them in order to determine their structure and the conformational changes 
occurring during substrate translocation. 
Chang and Roth In 2001 described the X-ray structure to a resolution of 4.5 angstroms 
of the E. coli homolog, MsbA, of the multiple drug resistance transporter (MDR1). MsbA is a 
lipid flippase that has a cone-like shape, organized as a homodimer with each subunit 
containing 6 transmembrane alpha-helices and a nucleotide-binding domain. 
Higgins and co-workers in 1997 described the shape of MDR1 (purified from Chinese 
hamster cells) using electron micrograph image analysis. The transporter looks like a 
cylinder with a diameter of 10 nm and a height of 8nm, it also has a central cavity with a 
diameter of 5 nm (Rosenberg et al 1997). 
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Up to now, two possible models exist to explain the mechanism by which ABC 
transporters perform the translocation: 
Flip-Flop (Rayes and Chang 2005) 
A TP switch model (Higgins and Linton 2004). 
Drug resistance and MDRlMRP 
In 1976 Juliano and Ling discovered a large glycoprotein in the plasma membrane of multiple 
drug resistant cells, the MDR1/ABCB1, and they considered it a primary active drug pump 
able to confer detoxification capacity to the cells that overexpress it. 
In 1992 Cole and coworkers defined MRP (now MRP1/ABCC1) as a second type of 
drug pump in multiple drug resistant cells. MRP1 was identified in a multidrug-resistant sub-
clone of a small cell lung carcinoma cell line (NCI-H69) that does not overexpress 
MDRlABCB1 (Cole et a11992; Roninson et a11986; Shen et a11986; Borst et a12000; Borst 
and Elferink 2002). 
In 1994 Leier demonstrated that MRP1/ABCC1 has a active GS-X pump activity 
(Glutathione conjugated compounds pump). The GS-X pump activity was studied in the 80s 
for its involvement in the Phase III elimination of conjugated organic anions produced by 
Phase I and Phase II detoxification metabolism of many endo- and xenobiotics; eliminated 
compounds are mostly glutathione, glucuronide or sulfate conjugated compounds (Ishikawa 
et aI1994). 
A MRP1 substrate is L TC4, which derives from arachidonic acid in a series of reactions 
that at the end culminate in glutathione conjugation (Ishikawa et aI1990). 
Definite proof that MRP1 can be the cause of multiple drug resistance came from 
transfection studies. HeLa cells transfected with MRP1 cDNA displayed a typical multidrug 
resistance phenotype, accompanied with a reduced intracellular drug accumulation. Similar 
behavior was found using other cell lines in different and independent laboratories (Cole et al 
1994; Grant et al 1994; Hipfner et al 1999). 
Newly synthesized MRP1 polypeptide migrates at approximately 170 kDa in SDS-
PAGE, consistent with a molecular mass of about 171 kDa predicted from its cDNA 
sequence. The immature form of the transporter is rapidly N-linked glycosylated, and the 
protein acquires a molecular mass of about 190 kDa (Almquist et aI1995). 
ABC transporters involved in drug resistance and peptide transport 
The ABCC/MRP sub-family is composed of twelve members and the ABCB/MDR sub-family 
of eleven members in humans. 
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These proteins have been identified as active, ATP-dependent membrane transporters 
for various drugs, organic anions with anticancer activity and also peptides. 
MDR1/PGY1/ABCB1 and MRP1-5/ABCC1-5 lead to multidrug resistance in tumor cells 
(Dean and Annilo 2005). 
Remarkably, in 2001 it was demonstrated that MRPlIABCC1 is able to translocate 
peptides across the plasma membrane (de Jong et al 2001). MDR1/PGY1/ABCB1, a 
member of the ABCB sub-family, was shown to transport a toxic peptide (ALLN) and other 
synthetic peptides across the cellular membrane (Sharma et al 1992; Lee et al 1999; Sarkadi 
et aI1994). 
Mostly peptide transport capacity has been described for some ABCB transporters sub-
family members, TAP1/ABCB2 (Antigen Peptide Transporter 1) and TAP2/ABCB3 (Antigen 
Peptide Transporter 2). TAP proteins are responsible for the translocation of antigenic 
peptides from the cytosol to the ER compartment of class I MHC expressing cells. MHC I 
molecules are synthesized in the ER and then exposed onto the cellular membrane already 
bound to the antigenic peptides. The membrane separating cytosol and the internal lumen of 
the ER is peptide impermeable, for this reason a pore or a transport molecule consuming 
energy is necessary to let the antigen enter the lumen. TAP proteins function as dimers 
composed of two subunits, TAP1 and TAP2, of about 75 kDa, which contain a NBF each. 
They are localized in the ER and cis-Golgi apparatus even if they do not possess the ER 
retention signal. TAP proteins are organized in a head-head/tail-tail orientation and the 
hetero-dimer forms a peptide binding pocket on the cytosolic side of the membrane in which 
TAP proteins are imbedded 0Ios et a11999; 2000). 
In 2001 Young found that the Saccharomyces cerevisiae ABC transporter Mdl1 is 
involved in peptide export from mitochondria. Mdl1 is homologous to human TAP proteins 
and belongs to the ABCB sub-branch. 
Moreover, ABCA1/CERP, a component of the ABCA sub-family, was suggested to be 
involved in the exocytosis of two leaderless proteins, IL-1beta and MIF (macrophages 
Migration Inhibitory Factor). These translocation studies were performed mainly using a 
pharmacological approach without giving a real and full demonstration of the molecular 
mechanism and an explanation of the translocation phenomenon. In this context 
Probencecid is reported as a specific drug inhibitor of the ABCC sub-family members by 
several people; Flieger in contrast observed a Probenecid inhibitory effect on ABCA 1 
transporter (We in et al 2004, Ferreira et al 2005a, Ferreira et al 2005b, Marty et al 2005, 
Hamilton et al 1993; Flieger et al 2003; Hamon et al 1997; Rubartelli et al 1990; Webster et 
al 2002; Michot et al 2006; Lucia et al 2005; Jorajuria et al 2004; Olson et al 2002). 
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A possible explanation of this conflict is that the cellular system that Flieger utilized is 
rappresentative only of the behaviour of monocyte/pro-macrophages, but not of the fully 
differentiated macrophages. Fully differentiated macrophages, however, are the main target 
of my studies and more specifically of the IL-1beta exocytosis inhibition experiments. 
Mrp1-1- mouse phenotype 
Mrp1-1- mice have defects in the innate and adaptive immune response (Wijnholds et al 
1997). In 2000 Robbiani et al showed that Mrp1-1- mice have impaired dendritic cell (DC) 
migration from skin to lymph nodes, and that the DC migratory ability can be partially 
restored by L TC4 administration. It was also shown that MK571 , an antagonist of MRP1, 
inhibits emigration of DCs from skin explants, and this suggested that MRP1 regulates DC 
migration by transporting L TC4. 
In 2001 Schultz et al showed that Mrp1-1- mice intranasally inoculated with Streptococcus 
pneumoniae were resistant to pneumonia. The mice displayed reduced inflammation marker 
levels in the lungs (TNF, IL-6, INFy) and diminished mortality, if compared with mice 
inoculated with saline. The author also described a block in the extracellular release of L TC4. 
In 2002 Verbon et al analyzed the T-helper 1 immune response in Mrp1-1- mice after 
intranasal inoculation of Mycobacterium tuberculosis. Two weeks after infection the mice had 
reduced levels of INFy, and reduced granuloma formation in lungs. 
The inflammation resistant phenotype of Mrp1-1- mice has been interpreted mainly as a 
consequence of impediment in the release of L TC4. 
Unfolding and transmembrane translocation 
Proteins have to fold into well-defined three dimensional structures to function correctly, but 
unfolding is also essential for several processes in the cell. Protein unfolding is a crucial step 
for importing some proteins into mitochondria or chloroplasts and in degradation of regulatory 
proteins by ATP-dependent proteases (Eilers and Schatz 1986; Rassow et al 1990; Walker 
et al 1996). The necessity of unfolding was demonstrated during ER import (Paunola et al 
1998) and lysosomal import (Salvador et al 2000). 
At the experimental level key findings have been made using mitochondrial reporter 
proteins and FGF-2, which were fused with dihydrofolate reductase (DHFR), an enzyme 
whose three-dimensional structure can be stabilized by the folate derivative, methotrexate 
(Eilers and Schatz, 1986; Wienhues et aI., 1991; Backhaus et al 2004). Employing the DHFR 
domain as part of a specific reporter molecule, protein translocation across a membrane can 
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be inhibited in the presence of methotrexate and for sure this kind of experiment is only an 
indirect proof of unfolding necessity for the whole reporter chimerical protein. 
In my work I utilize the chimera between HMGB1 and DHFR and methotrexate treatment to 
indirectly demonstrate that HMGB1 exocytosis unfolding is needed. Is reasonable that 
HMGB1 must unfold because of MRP1 tight pore and gate, even if, as I seed before, this 
experiment is only unindirect explanation of the translocation mechanism, but it seems 
reasonable to say that HMGB1 can not go thought MRP1 without modifying its structure for 
steric reasons. 
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Materials and Methods 
Chemicals and antibodies 
Glybenclamide (Sigma G0639). Ethacrynic Acid (Sigma E4754). 4,4' diisothiocyanatosilbene-
2.2'- disulfonic acid disodium salt (OIOS) (Sigma 03514), Probenecid (Sigma P8761). 
Verapamil (Sigma V4629). lipopolysaccharide (LPS) (Sigma L2654). Phorbol 12-myristate 
13-acetate (PMA) (Sigma P8139). LPS binding protein (LBP) (HBT HC4010). 
Lysophosphatidylcholine (LPC) (Sigma L4129). Adenosin-5'-triphosphate disodium salt 
(ATP) (Boehringer 519979. dissolved in H20 pH 7.2. 20mM). L-buthionine-sulfoximine (BSO) 
(Sigma B2515). Methotrexate (Sigma M8407). MK571 (Alexis). reduced glutathione (GSH) 
(Sigma G1404). oxidised glutathione (GSSG) (Sigma G4376). glutathione reductase 
(EC1.6.4.2) (Sigma G3664). NAOPH (Sigma N 1630). N-Ethylmaleimide (Sigma E1271). 
Hydrogen Peroxide- H202 (Sigma U8879) 
Monoclonal antibody anti-IL-1beta (Cell Signaling 2022). monoclonal antibody anti-
MRP1 (human QCRL-3) (Alexis 801011 L001), monoclonal mouse anti-MRP1 (Chemicon 
MAB4147). polyclonal antibody anti-HMGB1 (BO 556528). monoclonal antibody anti-C014 
(BO 555396). monoclonal antibody anti-beta-actin (Sigma A5441). monoclonal antibody 
against glutathione bound to protein (PSSG) (ViroGen 101-A). polyclonal antibody anti-LOH 
(Chemicon AB1222). 
E. coli strains 
OH5a: Strain with genotype supE44 DlacU169 (FBO lacZDM15) hsdR17 recA1 end 
A 1 gyrA96 thi-1 relA 1. A recombinant-deficient suppressing strain used for plating and 
growth of plasmids. 
BL21(-): Strain with genotype hsdS gal (A cltsB57ind 1 Sam7 nin5IacUV5-T7 gene 1). 
A strain used to express at high levels genes under the control of T7 promoter. It lacks the 
plasmid pLysE. coding for T7 phage lysozyme which inhibits the RNA polymerase basal 
activity. 
E. coli bacteria were generally grown in LB (Luria-Bertani) Medium. supplemented with 
selective antibiotics. 
LB (per liter) bacto-tryptone 10 g ; bacto-yeast extract 5 g; NaCI 10 
Primary cells and cell lines 
Primary mouse macrophages were isolated by peritoneal washing. Mice were injected with 3 
ml of a 3% thioglycollate solution in the peritoneal cavity. After 2 or 3 days. mice were ether 
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anesthetized, and injected intraperitoneally with 5 ml PBS (Gibco); after 10 min the fluid was 
recovered. Macrophages were incubated in RPMI 1640 (Gibco) complete medium plus 20 
tJM beta-mercapthoethanol for 5 hours immediately after extraction from the peritoneum. 
They were then cultured in RPMI 1640 complete medium supplemented with 10% fetal calf 
serum (FCS-Gibco), 2 mM L-glutamine (Gibco), 100 Ulml penicillin (Gibco), 100 /lg/ml 
streptomycin (Gibco). 
The human pro-monocytic THP-1 cell line, established from a diffuse histocytic 
lymphoma, is an in vitro model of monocyte to macrophage differentiation. THP-1 cells were 
maintained in complete RPMI1640 medium (Gibco) supplemented with 10% fetal calf serum 
(FCS), 2 mM L-glutamine, 100 Ulml penicillin, 100 /lg/ml streptomycin, or OptiMem (Gibco), 
and differentiated into macrophages by treating with 200 nM PMA for 3 to 48 hours. 
StimUlation with LPS (5 tJg/ml) was performed 18 to 48 hours after the end of differentiation. 
THP-1 cell line was a Massimo Alessio kind gift. 
Human ovarian carcinoma 2008 cells, and stable transfectants thereof -2008(MRP1), 
2008(MRP2), 2008(MRP3) and 2008(MRP5}- were a kind gift from Piet Borst. These cells, 
HeLa cells and stable transfectants from thereof -HeLa(sCD14), HeLa(MRP1), 
HeLa(MRP2), HeLa(MRP3), HeLa(MRP5), HeLa(MDR3) and HeLa(CFTR}- were cultured in 
complete DMEM (Gibco) supplemented with 10% fetal calf serum (FCS), 2 mM L-glutamine, 
100 Ulml penicillin, 100 ug/ml streptomycin (Gibco), or OptiMem (Gibco). 
HeLa cell line were cultured in complete DMEM (Gibco) supplemented with 10% fetal 
calf serum (FCS- Gibco), 2 mM L-glutamine, 100 U/ml penicillin, 100 /lg/ml streptomycin 
(Gibco), or OptiMem (Gibco). HeLa cell line was available in Marco Bianchi's laboratory. 
C1 cell line (Hmgb1-1- mouse fibroblasts) were cultured in complete DMEM (Gibco) 
supplemented with 10% fetal calf serum (FCS- Gibco), 2 mM L-glutamine, 100 U/ml 
penicillin, 100 /lg/ml streptomycin (Gibco), or OptiMem (Gibco). C1 cell line was available in 
Marco Bianchi's laboratory and was generated by Paola Scaffidi. 
Protein secretion 
One million THP-1 cells were plated in 3 cm wells, and differenced into macrophage as 
described above. One day after PMA induced differentiation, cells were stimulated overnight 
with 5 tJg/ml LPS in OptiMem (Gibco) medium (1 ml) in the presence or absence of various 
inhibitors (glybenclamide 250 tJM, DIDS 150 tJM, ETA 50 tJM, Probencid 2 mM, Verapamil 
100 tJM and MK571 50-300 tJM. Degranulation of secretory Iysosomes was activated adding 
0.5 tJM ATP 15 min before supernatant collection. Proteins in cell supernatants were 
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precipitated in 50% acetone, and resolved by reducing SDS-PAGE. HMGB1, IL-1beta were 
detected by western blotting. 
TLR4 activation 
The HeLa(sCD14) stable transfectant releases sCD14 in the supernatant. Medium 
conditioned by HeLa(sCD14) cells was collected, filtered and supplemented with 2 ~gLml 
LPS and 100 ng/ml LBP. The medium containing LPSILBP/sCD14 was used to activate 
TLR4 He La (or 2008) derived cell lines. 
Soluble CD14 (sCD14) cloning 
sCD14 cDNA sequence was amplified by Total RNA was extracted with TRlxol (Invitrogen) 
from PMA-differentiated THP-1 cells, and RT-PCR was performed using the primers 
sCD14Fw gtc ceg gat ccc cac cat gga gcg cgc gct ctg c and sCD14Rev tcc agg aat tct tac 
agc acc agg att cee ga). The RT-PCR product was then cloned BamHIIEcoRI in the pcDNA-3 
mammalian expression vector. The construct was transfected in HeLa cells using FuGENE6 
(Roche), G418-resistant clones were isolated and tested for sCD 14 production by 
immunofluorescence. 
ABC transporter cloning 
MRP1 cDNA was amplified by PCR from pj30mega-MRP1 (X_78338), a gift from P. 
Borst, using the primers MRP1 Fw aaa gat atc atg geg ctc egg ggc ttc and MRP1 Rev aaa 
gcg gcc gc tac aac caa ttc ctc, and then cloned in pcDNA (EcoRV/Notl). 
MRP2 cDNA was amplified by PCR from pGEM3-MRP2 (U_ 49248), a gift from P. 
Borst, using the primers MRP2Fw aaa aag ctt atg ctg gag aag ttc tgc and MRP2Rev gaa ttt 
tgt gct gtt cac att, and then cloned in pcDNA (Hindlll). 
MRP3 cDNA was amplified by PCR from pGEM7-MRP3 (AF _009670), a gift from P. 
Borst, using the primers MRP3Fw aaa gaa ttc atg gac gce etg tgc ggc and MRP3Rev aaa etc 
gag ctc atc agc ttg atg egc, and then cloned in peDNA (EeoRllXhol). 
MRP5 cDNA was amplified by PCR from pGEM5-MRP5 (NM_005688), a gift from P. 
Borst, using the primers MRP5Fw aaa aag ett atg aag gat atc gac ata gga and MRP5Rev 
aaa gaa tte gcc ett gae age gae ett, and then cloned in pcDNA (HindIlIlEcoRI). 
CFTR eDNA was amplified by PCR from pBS-CFTR (NM_000492), a gift from M. 
Conese, using the primers CFTRFw.: aaa ggt acc atgcag agg teg cct etg and CFTRRev aaa 
ctc gag aag eet tgt ate ttg cae, and then cloned in peDNA (KpnllXhol). 
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MDR3 cDNA was amplified by PCR from pj30mega-MDR3 (M_23234) from ATCC 
using the primers MDR3Fw aaa aag ctt atg gat ctt gag gcg gca aag and MDR3Rev aaa ccc 
ggg taa gtt ctg tgt ccc agc, and then cloned in pcDNA (HindIiIlEcoRV). 
The plasmids were transfected in HeLa cells using FuGENE6 (Roche) following 
manufacturer's protocol. ABC transporter overexpressing cell clones were isolated by limiting 
dilution approach after G418 (400J.lg/ml) selection, thanks to the neomycin resistance given 
by the transfected plasmidic construct. Each cell clone was analyzed by immunofluorescence 
(as described elsewhere in the thesis) using antibodies addressed against the different ABC 
transporters, in order to test for transporter plasmamembrane localization, and level of 
overexperssion (untransfected cells as negative control). The overexpressed ABC 
transporters were considered functional once were found expressed on the cell 
plasmamembrane even if formal poof was not provided. 
Immunofluorescence 
Primary macrophages were plated on acid-washed glass coverslips and maintained in the 
appropriate culture medium and experimental conditions. Immunofluorescence and imaging 
was described in Bonaldi et al (2003). In brief, cells were fixed in PHEM buffer (36.8 gIl 
PIPES, 13 g/l HEPES, 7.6 g/l EGTA, 1.99 g/l MgS04, titrated to pH 7.0 with KOH) plus 3.7% 
paraformaldehyde (PFA) for 15 minutes at room temperature. Cells were then treated for 5 
minutes with HEPES-based permeabilization buffer (300 mM sucrose, 0.2% Triton X-100) 
and then for 15 minutes with Blocking buffer (3% Bovine Serum Albumin in PBS). Primary 
and secondary fluorophore conjugated antibodies were diluted in PBS+BSA 0.2%. Hoechst 
33342 (1.5 \.Ig/ml) in PBS+BSA 0.2% was used as counterstaining. 
Cells expressing GFP fusion proteins were PFA-fixed, Hoechst 33342 stained and 
imaged. 
Cells were imaged using an Olympus 100x or 60xl1 .4NA Plan Apo oil immersion 
objective lens on a DeltaVision Restoration Microscopy System (Applied Precision, Issaquah, 
WA, USA) built around an Olympus IX70 microscope equipped with mercury-arc 
illumination. Filters were from Chroma Technology Corp. (Brattleboro, VT, USA): Hoechst 
33342 excitation 360/40, emission 457/50; GFP excitation 490/20, emission 528/38. Twenty 
optical sections spaced by 0.5 IJm were collected with a Coolsnap_Hq/lCX285 CCD camera 
(Photometrix, Tucson, AZ., USA) and deconvolved by the constrained iterative algorithm 
available in the SoftWoRx 2.50 package (Applied Precision) using 10 iterations and standard 
parameters. Each image measured 512x512 pixels, and effective pixel size was 0.106IJm. 
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Immunoprecipitation 
THP-1 cells, PMA differentiated and LPS stimulated, were lysed in JS buffer (50 mM HEPES 
pH 7.5, 150 mM NaCI, 1% Glycerol, 1% Triton-X100, 1.5 mM MgCI2); the protein 
concentration was determined by Bradford protein assay. Whole cells lysate (1 mg of in 500 
jJl final volume) was incubated with Dynabeads protein G (2 jJg, equal to 34 million beads) 
(Oxoid) for 1 hour at 4'C. Beads were washed using JS buffer before loading. 
Radiolabelling of the GSHlGSSG intracellular pool. 
Radiolabelling and protein synthesis block was performed as described in Fratelli et al (2003; 
2002). Experiments were performed in presence or absence of BSO 20 jJM. HMGB1 was 
immunoprecipitated from THP-1 cell lysate (after PMA differentiation and LPS stimulation) 
avoiding all reducing agents. In brief, macrophages derived from THP-1 cells were pre-
incubated for 1 hour in HBSS (Hanks' balanced salt solution, Gibco) with 50 jJg/ml 
cycloheximide and then stimulated with 5 jJg/ml LPS in the presence of 8 mCi/ml L-[35S]-Cys 
(specific activity 1000 Ci/mmol). Cells were lysed using JS buffer plus 50 mM N-
ethylmaleimide, MRP1 and HMGB1 were immunoprecipitated as described above, and 
samples were resolved by non-reducing SDS-PAGE. Radioactivity incorporation was 
detected by autoradiography of the dried gel. 
HMGB1-OHFR-GFP chimeric protein and unfolding assay 
Human DHFR cON A (NM_000791) was amplified by RT-PCR from total RNA extracted from 
HeLa cells using the primers DHFRFw ata aag ctt atg gtt ggt teg cta aac tgc and DHFRRev 
ata acc ggt aaa tca ttc ttc tca tat act. Rat HMGB1 cDNA (NM_012963) was amplified by PCR 
from pEGFP-HMGB1 (Scaffidi et al 2002) using the primers B1 Fw.: ata ctc gag atg ggc aaa 
gga gat cct aag and B 1 Rev ata aag ctt ttc atc atc atc atc ttc ttc; the PCR product was cloned 
in pEGFP-N1 (XhoI/Hindlll) and DHFR orf was cloned in frame with HMGB1 (HindIll/Agel). 
HeLa(MRP1) cells were transiently transfected with pEGFP-N1/HMGB1 (Scaffidi et al 
2002) and pEGFP-NlIHMGB1/DHFR. One day after transfection, the cell medium was 
changed with HeLa(sCD14 )-conditioned OptiMem supplemented with LPS (2 jJg/ml) and LBP 
(100 ng/ml) to activate TLR4, in the presence or absence of 20 IJM methotrexate (MTX). The 
day after, cell supernatants were precipitated with 50% acetone and westem blotting with 
anti-GFP was performed. 
26 
Materials and Methods 
Cysteine to Serine HMGB1 mutants 
Single and triple cysteine-to-serine HMGB1 mutants (C22S, C44S, C10SS and C22/44/10SS) 
were generated by site directed mutagenesis using Pfu DNA polymerase (Promega), 
pEGFP-HMGB1 (Scaffidi et a12002) as template and the following primers: 
1) HMGB1_Cys_Fw1: aaa ctc gag atg ggc aaa gga gat 
2) HMGB1_Cys_Rev1 : ccg act agt ttg cac aaa aaa tgc ata 
3) HMGB1_Cys_Fw2: gtg caa act agt cgg gag gag cat aag 
4) HMGB1_Cys_Rev2: tga act ctt ctt aga aaa ctc tga gaa 
S) HMGB1_Cys_Fw3: tct aag aag agt tca gag agg tgg aag 
6) HMGB1_Cys_Rev3: aga act gaa gag gaa gaa ggc cga agg 
7) HMGB1_Cys_Fw4: ttc ctc ttc agt tct gag tat egc cca 
8) HMGB1_Cys_Rev4: ttt gaa ttc ttl cat cat cat cat ttc 
Primers 2 and 3 mutagenise cysteine 22, primers 4 and S mutagenise cysteine 44, and 
primers 6 and 7 mutagenise cysteine 10S. Primers 1 and 8 amplify all HMGB1 orf adding 
Xhol and EcoRI restriction sites. Mutant HMGB1 PCR products were cloned in pEGFP-N1 
and pcDNA eukaryotic expression vectors. After HMGB1 mutant cloning all the vectors were 
sequenced by Primm s.r.1. (Milano, Italy) after a restriction analysis was performed. The 
plasmids were transfected in HeLa or C1 cells using FuGENE6 (Roche) following 
manufacturer's protocol (G418 selection was not applied) and protein expression was tested 
by fluorescence microscopy (GFP tagged) or whole cell Iysates western blotting analysis 
against HMGB 1. 
Real time-PCR Analysis 
The analysis was performed to test MRP1 (NM_008S76.2) MRP2 (NM_013806.1) and MRP3 
(NM_029600.2) mRNA expression level in mouse primary macrophages. 
Total RNA was extracted from primary macrophages (peritoneal wash of Mrp1-1- and wt 
mice) using TRlzol (Invitrogen) and according to the manufacturer's instructions. Total RNA 
was quantitated by spectrometry and A260lA280 ratios were determined. The mRNA level of 
a housekeeping gene, GAPDH (NG_00S233.1), was used to normalize different experiments 
and different total RNA samples, testing serial dilutions of the total RNA; amounts ranging 
from S to SOO ng (linear regression analysis). 
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2 Ilg of total RNA were treated with DNAse IIRNAase free (Promega) and reverse 
transcribed using Superscript II Rnase H reverse transcriptase (Life Technologies) and 
0Iigo(dT)16 as a template primer (as manufacturer described). 
First cONA stand was diluted (1 :500) and quantified by LightCycler instrument (Roche) and 
LightCycier fast Start DNA master(plus) SYBR green Kit (Roche); procedure was performed 
as described by the manufacturer. 
To quantify MRP1, 2 and 3 mRNA levels, the number of MRPx mRNA copies in WT and KO 
samples were divided by the amount of total RNA (in nanograms) determined by the number 
of GAPDH mRNA copies in the same sample. MRPx mRNA levels in these experiments 
were expressed as the mean copy number of MRPx mRNA molecules in 15 ng of total RNA 
(each quantification was performed in triplicate). 
The primers used were the following: 
Mouse MRP1 
Mouse MRP2 
Mouse MRP3 
Mouse GAPOH 
Fw1 .: gta gag ttc egg gat tac 
Rev1.: egc agg ttg tgc agg ceg at 
Fw2.: tgg ctg aga teg gag ag 
Rev2.: ttt gtc ctt tca cta ctt c 
Fw3.: egc tct cag ctc acc atc at 
Rev3.: ggt cat ceg tct cca agt ca 
Fwg.: gaa agc tgt ggc gtg atg 
Revg.: tga ata egg eta cag caa ca 
Recombinant HMGB1 glutathionylation in vitro 
Redox reactions were performed in a 1.5 ml Eppendorf tube in 50 ~f reaction volume (buffer: 
0,2 mM NaP pH 7.5, 2 mM NaCl, protease inhibitor (Complete-Roche)) for 5 minutes at room 
temperature. Reagent concentrations were: 20 ~gLml rHMGB1 (714 nM), 4 ~M GSH, 4 ~M 
GSSG: 4 ~M H20 2, 4 ~M NAOPH, 60 Ulml glutathione reductase. Samples were resolved by 
non-reducing 12% SOS-PAGE. Gels were stained with Coomassie or analysed by western 
blotting with anti-HMGB 1 . 
Glutathione reductase is a f1avoenzyme which utilises NADPH as electron donor. One 
enzyme unit is defined as the quantity of protein that reduces 1 ~mole of GSSG to GSH in 1 
min at pH 7.6 and 25'C. 
Recombinant HMGB1 expression and purification 
The plasmid pT7-7-rHMG1 used for expression of recombinant full-length HMGB1 in bacteria 
was a kind gift of prof. J.O. Thomas (Cambridge University, UK). 
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rHMGB1 was produced in the BL21(-) E. coli strain, following the protocol of Studier and 
Moffatt (1986), but with some modifications: briefly, M9 medium was used instead LB (per 
liter) bacto-tryptone 10 g ; bacto-yeast extract 5 g; NaCI10 g. 
5 X M9 salts (per liter): 
Na2HP04 . 7H20 64 9 
KH2P04 159 
NaCI 2.59 
NH4CI 59 
M9 (per liter): 
5 X M9salts 
1 M M9S04 
1 M CaCI2 
completed with: 
Cas-aminoacids 20 giL 
Glycerol 0.5% 
Yeast Extract 5g/L 
Glucose 0.4% 
200ml 
2ml 
0.1% 
Chloramphenicol 1001-191 ml 
BL21 (-) E. Coli transformed with pT7-7-rHMG1 were pre-inoculated in 300 ml medium oln, 
then inoculated in 3 L medium (37'C, shaking 200 rpm). IPTG (0.5 mM) was added to the 
culture when the 0.0.=0.7 (RT, shaking 100 rpm). Bacteria were left to grow for 16 hours, 
then they were collected by centrifugation. Bacteria were resuspended in Buffer L2 (50 mM 
Tris-HCI pH 8.0, 20 mM EOTA, 0.5 mM OTT, 0.5 mM PMSF), using sonication to clarify. 
NaCI was added to a final concentration 0.5 M and the extract was centrifuged to pellet the 
debris. 
The first purification step is a differential precipitation obtained by adding (NH4 )2S04 to 60% 
solubility: HMGB1 remains in solution. After 30 minutes on ice, the extract was centrifuged at 
10 000 rpm (Heraeus centrifuge model Sepatech GmgH) for 30 minutes. The supernatant 
was collected, filtered (20 !-1m) and loaded on a Phenyl-Sepharose Column (Amersham 
Pharmacia), connected to a FPLC System. rHMGB1 is eluted with stepwise decreasing 
(NH4)2S04 saturation (60%- 50%- 40%- 30%) generated by mixing the following buffers: 
buffer A 20 mM HEPES pH 7.9 buffer B 20 mM HEPES pH 7.9 
0.5 mM DTT 0.5 mM OTT 
0.2 mM PMSF 
0.2 mM EOTA pH 8.0 
0% (NH4 )2S04 
0.2 mM PMSF 
0.2 mM EOTA pH 8.0 
60% (NH4)2S04 
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Positive fractions were dialysed overnight in buffer A' (see below) and loaded on a Hi-Trap -
SP column (Amersham Pharmacia) connected to a FPLC System (Amerhsam Pharmacia). 
rHMGB1 was eluted in an increasing gradient of NaCl, mixing the following buffers: 
buffer A' 50 mM Hepes pH 7.9 buffer B' 50 mM HEPES pH 7.9 
0.5 mM on 0.5 mM on 
0.2 mM PMSF 
20 mM NaCI 
0.2 mM PMSF 
1 M NaCI 
rHMGB1 was concentrated in Centricon Cartridges (Millipore) and desalted in final Buffer G; 
the final concentration was evaluated both by Bradford Method and by Coomassie Staining 
on 12% SOS-PAGE. 
Buffer G: 
10 mM NaP pH 7.5 
100 mM NaCI 
0.5mM on 
mM PMSF. 
20 gel electrophoresis 
About 50 IJg of purified HMGB1 or 250-400 IJg of protein from total extracts were added to 
350 IJI rehydration buffer (8 M urea, 2% CHAPS, 20 mM dithioerythritol, 0.8% IPG buffer, 
carrier ampholytes pH 3-10 Non Linear or pH 4-7 Linear). Samples were applied onto 
ceramic strip holders (Pharmacia Biotech) connecting two electrodes, in contact with 18 cm 
polyacrylamide gel strips (pH range: 3-10 not linear, or pH 4-7 linear). Isoelectrofocusing 
(IEF) was performed on IPGphor (Pharmacia Biotech) with 2 different protocols according to 
the length of the strip: 
18 em strip protocol: 
-rehydration: 30 min at 20'C 
-IEF: 18'C 
-s 1: step-n-hold 30 V. 10.0 hours 
-S2: step-n-hold 200 V. 1.5 hours 
-S3: gradient 3500 V. 2.5 hours 
-54: step-n-hold 3500 V. 2.0 hours 
-S5: gradient 8000 V. 1.5 hours 
-56: step-n-hold 8000 V. 6.0 hours 
IEF was stopped after 75000- 90000 V/h. 
7 em strio protocol: 
-rehydration: 30 min at 20'C 
-IEF 18'C 
-S1 :step-n-hold 30 V. 10.0 hours 
Second dimension electrophoresis was performed using a Protean II apparatus (Bio-Rad). 
Strips were soaked first in Equilibration buffer (EB: 6 M urea, 3% SOS, 375 mM Tris pH 8.6, 
30% glycerol, 2% OTE), then in EB containing 3% iodoacetamide (1M) and traces of 
bromophenol blue (BBP). Subsequently, strips were applied onto 10%-12% PA gels. 
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First experimental hypothesis 
As described in the Introduction section, HMGB1 is normally present in the nucleus of 
macrophages and translocates into the cytosol after hyper-acetylation is induced by 
inflammatory Signals (Bonaldi et al 2003). This finding does not explain how HMGB1 can 
translocate across the plasma membrane. HMGB1 does not possess a leader sequence and 
for this reason can not enter the normal exocytotic pathway (endoplasmic reticulum/Golgi 
apparatus) but it is inside secretory Iysosomes in macrophages (Gardella et aI2002). 
Few proteins share with HMGB 1 this behavior; one of these is the pro-inflammatory 
cytokine IL-1beta. It was shown by electron microscopy that HMGB1 and IL-1beta co-localize 
inside the secretory Iysosomes (Gardella et al 2002); pharmacological analysis suggested 
the implication of ABCA 1 in the process of IL -1 beta exocytosis in human primary 
macrophages (Hamon et al 1997). 
My supervisor and I hypothesized the implication of the ABC transporters also in 
HMGB1 exocytosis, and to demonstrate this I utilized at first two different experimental 
approaches, a pharmacologic and a genetic one (gain of function and loss of function 
assays). 
Pharmacological dissection of the ABC transporter superfamily 
I tested the ability of many drugs, which were previously described to have differential 
inhibitory activity on various ABC transporter sub-branches (Hamon et al 1997, Wein et al 
2004, Ferreria et al 2005, Ferreira et al 2005bis, Marty et al 2005, Hamilton et al 1993), in 
blocking HMGB 1 exocytosis. 
The drugs I used and their corresponding ABC transporter inhibitory activity (reported in 
several but not fully exaustive pubblications) are; 
Glybenclamide, Ethacrinic Acid: All branches (Nofer et al 2006; Becq et al 1997; 
Silva et al 2004; O'Connell et al 2004; Conseil et al 2005; Kalin et al 2004; Wheeler et 
aI2000;JietaI2004) 
DIDS: ABCA; ABCD; ABCC(SUR); ABCG; ABCF; ABCE (Reddy et al 2002; Xia et al 
2005; Marty et al 2005; Becq et al 1997; Hamon et al 1997) 
Verapamil: ABCB (Ferreira et al 2005a; Ferreira et al 2005b; Griffin et al 2005; 
Roman et a12001) 
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Probenecid: ABCC (Webster et al 2002; Michot et al 2006; Lucia et al 2005; Jorajuria 
et al 2004; Olson et al 2002; Ferreira et al 2005a) 
Analysis of cell supernatants 
Each drug was tested on THP-1 cells for its ability to block HMGB1 release. THP-1 is a 
human pro-monocytic cell line that for this experiment was differentiated into macrophagic 
phenotype by PMA treatment and then LPS stimulated (figure 14 upper panel). As a control I 
tested for the release of IL-1 beta in the presence of the same drugs (figure 14 lower panel). 
The protein release in THP-1 cell supernatants was analyzed by western blotting, on 
samples precipitated with acetone. Absence of drug-induced cell necrosis was tested by 
detection of beta-actin or pro-IL-1 beta in the supematants. 
Drug control Ghb ETA Prob DIDS Vera 
50 pM 50 pM 2mM 150 pM 100 pM 
L 5 L 5 L 5 L 5 L 5 L 5 
actin 42 kDa 
HMGBl 30 kDa 
WB with anti-actin and anti-HMGB1 
32kDa 
IL -113 17 kDa 
WB With anti-IL-l ~ 
14) Activity of ABC transporter inhibitory drugs on HMGB1 and IL-1beta release 
The upper panel shows anti HMGB1 and anti beta-actin western blots on Iysates (L) and supernatants (8) of 
THP-1 cells treated with the different drugs. No actin is detectable in the supernatants. HMGB1 release is blocked 
by Glib (HMGB1), ETA (ethacrynic acid) and Prob (probenecid), DID8 (4,4'-diisothiocyanostilbene-2,2'-
disulfonic acid disodium salt) and Vera (verapamil) have no inhibitory effect. 
The lower panel shows anti IL-1beta western blots on Iysates (L) and supernatants (8) of THP-1 cells 
treated or untreated with the different drugs. No cytosolic pro-lL-1 beta is detectable in the supernatants. IL-1 beta 
release is blocked by Glib (HMGB1), ETA (ethacrynic acid) instead Vera and Prob have no inhibitory effect. 
This experiment was repeated 3 times. 
Immunofluorescence analysis 
Figure 15 shows an immunofluorescence against HMGB1 on mouse primary macrophages 
LPS stimulated in presence or absence of the different drugs. 
Glybenclamide, ETA and Probencid inhibited HMGB1 loading inside macrophagic 
secretory Iysosomes; on the contrary DIDS and Verapamil did not show any effect. 
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The immunofluorescence results confirm the western blots. 
15) Activity of ABC transporter inhibitory drugs on the loading of HMGB1 inside secretory Iysosomes 
Immunofluorescence images show anti-HMGB1 (red) in wt mouse primary macrophages (nudei are 
counterstained blue). Macrophages were activated with 2 ~gLml LPS in presence or absence of the different 
inhibitors for 18 hours. Glib, ETA and Prob block HMGB1 loading into vesides. DIDS and Vera did not show 
effect. This experiment was repeated 5 times isolating macrophages from healthy mice. Scale bar is 81lm. 
The graph shows the intersection of sets ABC transporters inhibited by the different 
drugs used in this study. Glib/ETA inhibit all the superfamily branches (from A to G). DIDS 
blocks the A, 0, E, F and G branches. Prob inhibits the B branch. Vera inhibits the C (MRP 
and Sur) branches. 
I have drawn an Eulero-Venn's diagram intersecting the different sets of ABC transporters 
inhibited by each drug (figure 15). The diagram output indicates the probable implication of 
the ABCC/MRP sub-branch in the process of active exocytosis of HMGB1. 
Genetic interactions between MRPs and HMGB1 
The previous experiments have shown the implication of MRP transporters in HMGB1 
exocytosis. To investigate in more detail the process, and to avoid errors due to side effects 
of the drug utilized, I used two genetic approaches, "gain of function" and "loss of function". 
Gain of function 
The gain of function assay is based on the observation of an additional ability in cells in 
which the level of expression of a molecule of interest is modified. 
The experimental hypothesis is that the overexpression of the different MRP/MDR 
molecules on the plasma membrane of "low-transporting" cells will allow them to release an 
increased amount of HMGB1 in the external environment. 
The experiment can be divided in two steps; 
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1) Generation of a stable HeLa cell line expressing sC014 constitutively (figure 16A), and 
therefore releasing this molecule in the medium. In this cell line, TLR4 activation and 
HMGB1 nucleus/cytosol translocation can be triggered by addition of LPS and LPS 
binding protein (LBP) in the medium (Backhed et al 2002). 
Figure 17 A shows that, in HeLa cells, HMGB 1-GFP translocates from the nucleus to 
the cytosol in the presence of the molecular complex sC014ILSP/LPS, which specifically 
activates the TLR4 pathway. It is possible to see the same effect using macrophage 
conditioned medium plus LPS. 
Figure 17B shows that in HeLa cells, after TLR4 activation, HMGB1 obtains the 
correct biochemical modification after nucleus/cytoplasm translocation. In the 20 western 
blotting, an additional HMGB1 spot appears, shifted in isoelectric point towards the acid 
pole, as described by Bonaldi et al in 2003. 
A Hela(sCD14) 
B 
16) A. sCD14 overexpression in Hela cells Immuno-fluorescence with anti-CD14 (green) on a stable HeLa 
clone overexpressing sCD14. sCD14 is expressed in the ER, Golgi apparatus, and secretory vesicles. The 
nucleus is counterstained blue. Scale bar is 811m. 
B. TLR4 expression. In the upper panel , semi-quantitative RT-PCR shows TLR4 expression in all cells used. 
Total RNA from HeLa, THP-1 and 2008 (parental , MRP1 , MRP2 or MRP3) cells was analyzed. In the lower panel 
the level of beta-actin is shown. 
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17) A. HMGB1 cytosol-nucleus translocation after TlR4 activation Fluorescence images show HMGB1-GFP 
translocation from the nucleus to the cytoplasm when the TLR4 pathway is activated in HeLa cells. Scale bar is 
2.5i1m. 
B. TlR4 activation induces HMGB1 hyperacetylation On the right of the fluorescence pictures the respective 
2D western blot with anti-HMGB1 is shown (about 500 f.Jg of total protein). After TLR4 activation an additional 
HMGB1 spot appears, at an isoelectric point shifted towards the acidic pole (asterisk). 
2) Selective overexpression of the various ABC transporters in cell lines expressing TLR4 
(Figure 16B). and subsequent test for HMGB 1 exocytosis. 
At this point I performed the gain of function experiment (Figure 18) and I noted that 
overexpression of MRP1. MRP2 and MRP3 allows HeLa cells to release high amounts of 
HMGB1 (Figure 18 upper panel) after TLR4 activation. The same TLR4 activation 
experiment was performed using 2008 human ovarian carcinoma cell lines 
overexpressing MRP1. MRP2 and MRP3 (Figure 18 lower panel) (Hooijberg et al 2003). 
and the result is similar to that obtained using HeLa cells. 
In HeLa-derived cell lines the membrane localization and overexperession of ABC 
transporters plasma was tested by immunofluorescence (as described in Materials and 
Methods section). I did not test for the actual functional transporters; this caveat means 
that the transporters that do not appear to translocate HMGB 1 into the external milieu 
may simply be not functional despite overexpression. 
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18) Gain of function experiment The figure shows western blotting with anti HMGB1 of supernatants of HeLa 
cells (upper panel) and 2008 human ovarian carcinoma cells (lower panel) overexpressing different ABC 
transporters. Cells that overexpress MRP1 , MRP2 and MRP3 acquire the capability to secrete HMGB1 . The HeLa 
cells experiment was repeated 5 times testing #2 dones for each construct. The 2008 cells experiment was 
repeated two times. 
Loss of function 
The second genetic approach I utilized to investigate MRP/HMGB1 interaction is shown in 
figure 19. Macrophages were isolated from Mrp1-1- and wt mice and then stimulated with 
LPS; at different time points supernatants were tested for HMGB1 release by western 
blotting with anti-HMGB1 antibodies. As expected, macrophages without the transporter 
molecule fail to release HMGB1 with high efficiency, if compared with the wt at the some time 
points. IL-1 beta is released by both Mrp1-1- and wt macrophages, so secretory Iysosomes 
have no degranulation defect. The absence of cell necrosis was tested by assaying for pro-
IL-1 beta in the supernatant. 
This experiment was repeated 5 times, both monitoring HMGB1 secretion from 
macrophages obtained from single individuals, and from pools of several individuals, with 
similar results . Figure 19 shows the time course of HMGB1 secretion . Statistical analysis 
(non-parametric Kruskal-Wallis ANOVA) shows the difference between Mrp1-1- and wt 
macrophages to be highly significant (P<O .01). However, it should be noted that, although 
MRP1 appears to be the major HMGB 1 
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19) Loss offunction in Mrp1-1- macrophages 
Results 
The upper panel shows a western blot anti HMGB1 and anti IL-1-beta on Mrp1-1- and wt macrophage 
supernatants, collected at different time points after LPS stimulation. IL-1beta is released by both cell types, 
although with slightly different kinetics. Pro-IL-1beta is used as cell necrosis marker and is detected in the 
supernatants after 2 days. 
The histogram shows means and standard deviations of the amount of HMGB1 released by 500 000 
Mrp1-1- and wt macrophages at different time paints after LPS stimulation . Each value is the average of results 
coming from 5 different experiments: 
1) Pool of 3 male and 2 female Mrp1-1- mice vs matched wt mice 
2) Mrp1-1- female 20 vs wt female 
3) Mrp1-1- female 3F vs wt female 
4) Mrp1-1- female 3E vs wt female 
5) Pool of 3 males Mrp1-1- mice vs matched wt mice 
Quantification was done by densitometry on western blots with anti HMGB1 using the ImageJ program. Values 
were normalized against HMGB 1 released by wt macrophages after 30 minutes, which was put equal to 1. 
Samples were analysed also for the presence of pro-IL-1beta (32 kOa), marker of cell necrosis, and IL-1beta (17 
kOa) markerof normal secretory Iysosomes degranulation. Statistical analysis (ANOVA Kruskal-Wallis two ways) 
shows that the differences between wt and Mrp1-I-macrophages is highly significant (p<O.01). 
The lower left panel show western blots on whole macrophage cell Iysates (Mrp1-1- and wt), collected 
after 18 hours of stimulation. The filters were probed with anti HMGB1, anti IL-1beta, anti beta-actin and anti-
C014 antibodies. HMGB1 is present also in a faster migrating form in Mrp1-1- macrophages. Beta-actin was used 
as a loading control. 
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transporter in mouse macrophages, most likely it is not the only one: a small amount of 
HMGB1 is also released by Mrp1-1- macrophages. 
Western blots with anti CD14, IL-1beta, HMGB1 and beta-actin on ceillysates collected 
after 18 hours of stimulation show no detectable differences between Mrp1-1- and wt 
macrophages, except for the appearance of a faster migrating HMGB 1 form (perhaps a 
degradation product) in Mrp1-1- macrophages. 
MRP expression level in mouse peritoneal macrophages 
In order to evaluate the expression level of MRP1, MRP2 and MRP3 in peritoneal 
macrophages. I performed real time PCR using the LightCycier (Roche) thecnology on 
cDNAs obtained from reverse-transcription of total RNA isolated from Mrp1-1- and wt 
macrophages. I used primers specific for mouse MPR1, MRP2 and MRP3 cDNAs. Known 
template quantities (linearized plasmids containing MRPx coding sequences) were used to 
draw a titration curve. Figure 20 shows the LightCycier screen shot of one explicative 
quantification reaction. LightCycler is able to measure fluorescence intensity patter (sigmoid) 
during the PCR cycling and this is directly proportional to the DNA quantity in each sample. 
PCR were performed on samples where the number of cDNA molecules was known 
(standard) or unknown (total RNA) and the software is able to draw a titration curve using as 
reference the given standard points, making a correlation between fluorescence intensity and 
the number of cDNA molecules. 
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20) Real time peR The graph shows the fluorescence intensity pattern during peR reactions which were 
performed on samples where the number of MRP1 cDNA molecules was known (standard) or unknown (total 
RNA). The software is able to draw a titration curve using as reference the standard points. making a correlation 
between fluorescence intensity and the number of cDNA molecules. 
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21) MRP1, MRP2 and MRP3 mRNA level in mouse peritoneal macrophages wt and Mrp1-1- This panel 
shows the quantification of mRNAs coding for MRP1 , MRP2, MRP3 in mouse peritoneal macrophages fYVT and 
Mrp1-1-). Data were collected from several experiments performed on totRNA derived from different macrophage 
isolations. MRP1 is expressed at extremely high level in comparison with MRP2 and 3. 
The results (Figure 21) indicate a significance expression for MRP1 in wt 
macrophages, and the absence of MRP1 expression in Mrp1-/- macrophages, as expected. 
MRP2 and MRP3 are expressed at low levels, both in wt and Mrp1-/- macrophages. 
Thus, even if MRP2 and MRP3 can transport HMGB 1, most secretion in 
macrophages would occur via MRP1. This is in accordance with the results obtained with 
macrophages from Mrp1-1- mice. 
MRP1/HMGB1 interaction and glutathione modification 
MRP1 is an ABC transporter characterized for its A TP dependent pump activity on GSH 
modifide compounds. GSH modification (GS-X) is also called glutathionylation and 
glutathione is an enzymatically synthesized tripeptide (Figure 23) which is used to maintain 
the intracellular redox potential, and acts as "garbage label" to identify toxic compounds. 
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GSH is synthesized in a series of biochemical reactions catalyzed by cysteine-glutamate 
ligase (GCCL) and Glutathione synthase (GSHS) which require ATP, magnesium and three 
amino acids: cysteine, glutamate and glycine. Glutathione binds its substrates by disulfide 
bridges using the cysteine sulfhydryl moiety. 
I tested for HMGB1 glutathionilation "in vitro" and "in vivo" (figures 24-29) by the fact that 
during my experiment I observed MRP1 playing its transporter activity onto HMGB1 and I 
hypothesized that glutathione could be a post-translational modification .necessary for the 
recognition between the two molecules. 
BSO 
Glu 1 Gy 
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ATP Aa~ ATP ADP 
23) Glutathione de novo synthesis Glutathione is composed of three amino acids, Glu, Cys and Gly. Its 
synthesis is catalyzed by two ATP dependent enzymes, Glu-Cys ligase (GCCL) and Glutathione synthase 
(GSHS). ssa blocks GSH synthesis acting on GCCL. 
I assayed for the presence of GSH covalently bound to HMGB1 using two approaches: 
1) HMGB1 reactivity to an antibody specific for GSH bound to protein (Figure 24) 
2) radiolabeling the GSH/GSSG intracellular pool, and testing whether HMGB1 
became radioactive (Figure 25). 
HMGB1 glutathionylation assay using anti-GSH antibody 
Figure 24 shows HMGB1 reactivity to anti-GSH antibody. HMGB1 was immunoprecipitated, 
in non reducing conditions. from THP-1 whole cell lysate. after treatment with PMA and LPS 
stimulation. 
32KDa 
25KDa 
not reduc ng 
SOS-PCIge 
WB 
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on on 
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24) Detection of HMGB1 glutathionylation using an anti-glutathione antibody HMGB1 was 
immunoprecipitated from THP-1 cells differentiated to macrophages and LPS-stimulated for 18 hours. The 
immunoprecipitated material was loaded in reducing (DTT) or non-reducing conditions on non-reducing SDS-
PAGE, and immunodetected with anti-HMGB1 and anti-GSH. HMGB1 is present in two different forms with 
different electrophoretic mobility, the slower form is recognized by the anti-GSH antibody. 
Samples were resolved by SDS-PAGE in non-reducing conditions and then probed with anti-
HMGB1 and anti-GSH antibodies; as control for the signal specificity reducing conditions 
were restored adding 20 IJM OTT. In non-reducing conditions HMGB1 displays two different 
forms(apparent molecular weight 35KOa and 28KDa), one of which is recognized by the anti-
GSH antibody. 
HMGB1 glutathionvlation assay bv GSHIGSSG intracellular radiolabelling 
The second experimental approach I utilized to investigate HMGB 1 glutathionylation was the 
radiolabelling of the GSH/GSSG intracellular pool. I gave a 35S-cysteine pulse to THP-1 cells 
differentiated to macrophages and activated with LPS, in the presence of protein synthesis 
block (cycloheximide) (see Materials and Methods). In these conditions radiolabelled 
glutathione can be synthesized de novo, since its biosynthetic pathway does not require 
ribosomal activity (Figure 23). 
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25) GSHlGSSG intracellular radiolabelling THP-1 cells differentiated to macrophages were stimulated with 
LPS. Protein synthesis was blocked with cycloheximide and GSH/GSSG intracellular pool was labeled with a 
35S-Cys pulse, in the presence (8) or the absence (A) of the GCCL inhibitor 8S0. Samples were collected at 
different time points after the beginning of LPS stimulation, and immunprecipitated with anti-HMG81 and anti-
MRP1 . The immunoprecipitated material was resolved by SOS-PAGE in non-reducing conditions. This 
experiment was repeated 2 times. 
HMGB1 and MRP1 were immunoprecipitated at different time points after the beginning of 
LPS stimulation. Samples were electrophoresed in non-reducing conditions and the 
incorporated radioactivity was measured by autoradiography. An increasing amount of 
radioactivity was associated to both HMGB1 and MRP1 with time (Figure 25a). 
GCCL catalytic activity can be inhibited by L-buthionine-sulfoximine (BSO), which 
binds covalently to a free thiol in the active site. Pretreatment with 20 !-1M Bsa blocks 
HMGB1 and MRP1 radiosignal incorporation (Figure 25b). 
HMGB1 secretion after blockage of glutathione synthesis 
To test whether glutathione is necessary for HMGB1 release, I depleted the GSH/GSSG 
intracellular pool. I pre-treated THP-1 cells differentiated to macrophages with increasing 
BSa concentrations (from 0 to 100 !-1M) for 8 hours before LPS stimulation . Supernatants 
were collected 18 hours after LPS stimulation . I tested for drug induced cell necrosis with 
anti-LDH antibody, and for IL-1beta and HMGB1 secretion . IL-1beta release is enhanced in 
the presence of BSO, as reported by Haddad in 2002. HMGB1 release is strongly impaired 
(Figure 26). 
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26) BSO inhibits HMGB1 secretion Western blot on supernatants of THP-1 cells differentiated to macrophages 
and pre-treated with BSO before LPS activation. The filter was probed with anti-LDH antibody, to detect drug 
induced cell necrosis, with anti·HMGB1 and anti-IL-1beta antibodies, to test for the amount of protein secretion. 
This experiment was repeated 2 times. 
In vitro gJutathionyJation of recombinant HMGB1 
To further understand the HMGB1 translocation mechanism, I investigated if HMGB1 
glutathionylation is a spontaneous process driven by redox potential or if it is an enzyme-
catalyzed reaction. 
Indeed, HMGB1 can be glutathionylated in vitro by incubating the recombinant protein 
(rHMGB 1) in the presence of reduced glutathione (GSH). Figure 24 shows that recombinant 
HMGB1 migrates in non-reducing SOS-PAGE as a series of bands (whereas it migrates as a 
single band in reducing conditions, not shown here). We infer that the slower running bands 
represent HMGB1 multimers, deriving from the formation of SS bonds between HMGB1 
monomers. After incubation with reduced glutathione (GSH), the putative HMGB1 multimers 
disappear, and a new band appears, migrating just above the unmodified HMGB1 monomer 
(apparent molecular weight 28KOa). 
The slowly migrating HMGB1 band is not produced after incubation of rHMGB1 with 
oxidized glutathione (GSSG), but is evident if HMGB1 and GSSG are incubated with 
glutathione reductase and NAOPH, which reduce GSSG to GSH (Figure 26). 
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27) Recombinant HMGB1 reacts with reduced glutathione in vitro Coomassie staining and Westewn blot with 
anti-HMG81 antibodies of recombinant HMGB1 (500 ng) before and after incubation with 4 IJM GSH, resolved in 
non-redudng SOS-PAGE. 
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28) Recombinant HMGB1 reacts with oxidized glutathione only in the presence of glutathione reductase 
and NADPH Coomassie staining of non-reducing SOS-PAGE loaded with recombinant HMGB1 (500 ng) after 
incubation with the indicated reactants: 
Hydrogen peroxide 4 IJ M 
GSH 4 IJM + hydrogen peroxide 4IJM 
GSSG 4IJM 
GSH 4IJM 
GSSG + glutathione reductase WID electron donor 
GSSG + glutathione reductase + NAOPH 
From these experiments I infer that HMGB 1 reacts spontaneously with reduced GSH. 
However, this does not exclude that a catalyzed reaction might occur inside the cell. 
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Comparison between in vitro and in vivo glutathionY/ated HMGB1 
In westem blots after non-reducing SDS-PAGE, anti-HMGB1 antibodies recognize two 
HMGB1 forms with different electrophoretic mobility; the slower band is also recognized by 
the anti-GSH antibody in the immunoprecipitation assay (figure 24). Figure 29 shows that, in 
THP-1 cells differentiated to macrophages, the slower band recognized by anti-HMGB1 
antibodies migrates with the same mobility of HMGB1 after incubation with reduced GSH; we 
therefore identify it as glutathionylated HMGB 1. The faster band has the same 
electrophoretic mobility as unmodified HMGB1. In unstimulated cells, the amount of 
glutathionylated HMGB1 is already signtficant; after stimulation of the cells with LPS, almost 
all HMGB1 is found in glutathionylated form. 
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29) Glutathionylation of recombinant and endogenous HMGB1 Western blot with anti HMGB1 antibodies 
after SOS-PAGE in non-reducing conditions. The gel was loaded with 0.5 ~g of recombinant HMGB1 treated or 
untreated for 5 minutes with 4 ~M reduced glutathione and whole Iysates of 500 000 THP-1 cells differentiated to 
maaaphages, stimulated with LPS or not for 18 hours. This experiment was repeated 2 times. 
HMGB1 cysteine residues 
A possible target for the formation of disulfide bridges with glutathione are cysteine residues. 
HMGB1 has three cysteine residues (number 22, 44 and 105) (figure 30a). I decided to 
abolish these thiols by mutating the 3 cysteines into serines. I generated 3 single cysteine to 
serine mutants, C22S, C44S and C105S, and one triple cysteine to serine mutant 
C22/44/105S. I transfected HeLa cells with wt and mutant forms of HMGB1 in fusion with 
GFP (Figure 30c) and I analyzed the subcellular localization of these proteins in normal 
conditions and after TLR4 activation . 
In unstimulated conditions, mutant proteins are expressed and have a nuclear 
localization like wt HMGB1, and after TLR4 activation translocate from the nucleus to the 
cytosol 
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30) HMGB1 cysteine mutants 
A. HMGB1 (Rattus norvegicus) nudeotide and amino add sequences, In green, cysteine residues. 
Results 
B Western blot with anti-HMGB1 of whole cell Iysates supernatants of Hmgb1-1- fibroblasts expressing different 
mutant or wt HMGB1. Samples were collected after TLR4 activation (18 hours). Wt and C22S HMGB1 are 
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normally released, instead eMS, C105S and C22I44/10SS are not detectable. Fibroblasts were transiently 
cotrnnsfected with MRP1 overexperssing construct (experiment was repeated 2 times). 
c. HeLa cells transfected with wt, C22S, C44S, C105S and C22/44/105S HMGB1 in fusion with GFP (in green). 
In normal unstimulated condrtions mutant proteins and wt are nuclear, after TLR4 activation (18 hours) they are 
partially cystosolic. Nudei are counterstained blue with Hoechst 33342. Scale bar is 8flm. The experiment was 
repeated 2 times. 
To test whether the HMGB1 mutants can be secreted via MRP1, I then cotransfected 
Hmgb1-1- fibroblasts with the MRP1 expression construct (pcDNA-MRP1) and wt or mutant 
HMGB1 vectors. I then stimulated these cells with LPS/CD14/LBP and tested the 
supernatants for secreted HMGB 1 (wt or mutant). The triple mutant C22/44/105S, and the 
single mutants CMS and C105S cannot be detected in the supernatant, instead the C22S 
mutant and wt HMGB 1 are normally secreted (figure 30b). 
MRP1 and HMGB1 molecular interaction 
MRP1-HMGB1 co-immunoprecipitation 
If HMGB1 traverses lipid membranes across MRP1, there might exist a quite stable if 
transient interaction between HMGB1 and MRP1 . I tried a co-immunoprecipitation assay 
using the anti-MRP1 monoclonal antibody QCRL-3, which recognizes an epitope on the 
intracellular side of the transporter in native conditions; it does not recognize the denatured 
epitope (Hipfner at al 1999). Remarkably, a faint but distinct band of HMGB 1 was detectable 
in the QCRL-3 immunoprecipitate. Control immunoprecipitations with no antibody, or an 
irrelevant antibody against lactate dehydrogenase, recovered no HMGB1 (figure31). 
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31) MRP1 and HMGB1 co-immunoprecipitation Whole Iysates of THP-1 differentiated to macrophages, after 18 
hours LPS activation, were Immunoprecipitated with the indicated antibodies. The beads were then boiled in SDS-
PAGE loading buffer, electrophores, and western blotted with anti-HMGB1. 
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Unfolding assay 
HMGB1 has a distinct non-globular structure (Knapp et al 2004) with 2 independent HMG 
boxes and a long unstructured tail. Each HMG box is composed of 3 alpha helices. I asked 
how it can traverse MRP1 , which looks like a cylinder which has an outer diameter of 10 nm 
and an internal cavity of a maximum of 5 nm and an even smaller central gate (Rosenberg et 
al 2001). HMGB1 might sneak through the MRP1 cavity retaining its folding, or it could 
thread through it after reversible unfolding. Notably, HMGB1 can refold spontaneously after 
thermal denaturation (Ramstein et al 1999). 
I generated a chimeric protein fusing HMGB1, DHFR and GFP (in that order from the N- to 
the C-terminus) and I tested whether it can traverse MRP1. HeLa cells overexpressing MRP1 
and HMGB1-DHFR-GFP did in fact secrete the fusion protein, after LPS/sCD14/LPB 
stimulation, albeit a much lower level than the HMGB1-GFP fusion protein (Figure 32). 
Methotrexate (MTX) binds tightly to the catalytic site of DHFR and prevents its unfolding 
(Eilers et al 1986); in the presence of MTX, the HMGB1-DHFR-GFP fusion was retained 
inside the cell, indicating that its unfolding is required for transport by MRP1. The control 
HMGB1 -GFP fusion was secreted at approximately the same level even in the presence of 
MTX. This experiment suggests that to be translocated in the extemal environment HMGB1 
and all the proteins in fusion with it must be unfolded, even if, this kind of experiment is only 
an indirect proof of unfolding necessity of the whole reporter chimerical protein. The some 
experiment was performed to test FGF-2 secretion (Backhaus et al 2004). 
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32) Unfolding-dependent HMGB1 translocation throughout MRP1 HeLa cells overexpressing MRP1 were 
tranSiently transfected with the chimeric proteins HMGB1-DHFR-GFP and HMGB1-GFP. After TLR4 activation, in 
presence or absence of 20 IJM methotrexate (MTX), cell supernatants and Iysates were analyzed by western 
blotting with anti-GFP. 
MK571 
The drug MK571, (E)-3-[[[3-[2-{7 -chloro-2-quinolinyl )ethenyl]phenyl]-[[3-dimethylamino )-3-
oxopropyl]thio]methyl]thio]-propanoic acid, was developed in 1989 by Jones and co-workers 
as a specific L TC4 receptor antagonist and subsequently (Jedlitschky et al 1994) it was 
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found that at much higher concentration (j.lM compared to nM) it can be a specific inhibitor for 
MRP1 and MRP2 (Chen et al 1999, van der Kolk et al 1998), but in different conditions 
MK571 can also inhibits MRP3 (Li et al 2003) and MRP4 (Chen et al 2002). 
Here I show an experiment in which I tested for MK571 inhibitory activity on HMGB1 and IL-
1 beta exocytosis (figure 30). I performed a western blotting on supernatants of THP-1 
derived macrophages, LPS stimulated , in the presence of MK571 increasing concentration. 
HMGB 1 exocytosis inh ibitory concentration range is around 30 j.lM and IL-1 beta exocytosis is 
not affected in the presence of MK571 . MK571 is overkilling at concentrations over 30 j.lM 
and it must be highlighted that th is result is preliminar because of the difficulty of maintaining 
cells alive during MK571 treatment. 
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33) MK571 and HMGB1 exocytosis The figure shows a WB on supernatants and whole cell lysate of THP-1 
derived macrophages (PMA O,5IlM) stimulated wi th LPS (5Ilg/ml ) in presence or absence of MK571 at increasing 
concentration Stimulation was performed for 18hrs. Pro-1 L-1 beta release is used as index of drug induced cell 
necrosis. 
MK571 is inhibitory for both HMGB1 at 30 11M, it is overkilli ng at concentrations higher than 150llM (pro-IL-1beta 
release). This experiment was performed in duplicate. 
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Discussion 
HMGB1 is a bi-functional abundant nuclear protein which plays a role in transcriptional 
regulation but also in inflammation and tumor growth (Lotze and Tracey 2005). HMGB1 has 
been associated with cancer growth and dispersal: antibodies against HMGB1 and decoy 
receptors for it (soluble RAGE) hinder the growth of the primary tumour mass and reduce the 
number of metastases (Taguchi et al 2000, Huttunen et al 2002). 
HMGB1 is actively released by competent cells, avoiding the canonical exocytosis 
route via ER/Golgi; HMGB1 does not possess a leader signal in its amino acid sequence 
(Nickel 2005, Degryse et al 2001, Schlueter et al 2005, Wang et al 1999). 
In my thesis work I identified and characterized the molecular mechanism by which 
HMGB1, as a leaderless protein, can be released in the external milieu with high efficiency 
and in a controlled manner. 
I have identified MRP transporters as the major players involved in the process, and 
HMGB1 glutathionylation as a necessary post-translational modification. 
Identification of MRP transporters as HMGB 1 carrier molecules was obtained 
approaching the experimental problem with different assays: 
a) Pharmacological transporter inhibition (figures 14 and 15) 
b) MRP transporter overexpression (figure 18) 
c) MRP transporter knock out (figure 19). 
The different drugs I used at the beginning allowed me to dissect the ABC transporter 
superfamily by inhibiting specific branches, one of which is the MRP branch. I observed that 
relatively unspecific compounds, such as ethacrynic acic (powerful inhibitor of all the ABC 
transporter superfamily), more specific compounds, such as probenecid (preferentially 
inhibits the ABCC branch), and finally specific inhibitors, such as MK571 (a drug designed to 
inhibit MRP1 and MPR2) all block HMGB1 release. 
Pharmacological treatments cannot fully prove direct molecular interactions between 
two perturbed cellular functions (MRP functionality and HMGB1 translocation), and this is 
due to drug side effects; for this reason I performed genetic tests of gain and loss of function. 
In the gain of function assay I observed that not only MRP1 by also MRP2 and MRP3 are 
able to translocate HMGB1 in the extemal environment. In the loss of function assay I 
observed that Mrp1-1- macrophages show a severe deficiency in HMGB1 secretion, but not 
in IL-1 beta secretion. Significantly, in macrophages MRP1 is by far the most expressed 
transporter of the MRP1, -2 and -3 trio (figure 19quater). However, even Mrp1-/-
macrophages release a small amount of HMGB 1. 
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Intriguingly, Mrp1-1- mice have an inflammation-defective phenotype, described since 
1997 (Wijnholds et al) in the laboratory Piet Borst. Moreover these mice show defects in DC 
migration to the lymph nodes (Robbiani et al 2000). So far, the functional interpretation of the 
inflammation defects of Mrp1-1- mice defects was ascribed to the inability to secret L TC4. 
HMGB1 is a late inflammatory mediator and is necessary for peripheral DC maturation 
(Dumitriu et al 2005), so the phenotype Mrp1-1- mice can in part be due to the absence of 
HMGB1 in some step of the inflammatory cascade, arguably in later phases. 
HMGB1 and IL-1beta, another leaderless cytokine, partially colocalize in 
macrophages secretory Iysosomes (Gardella et al 2002), even if the exact characterization of 
these acidic organelles needs additional studies. In Mrp1-1- macrophages IL-1 beta loading 
and release is not affected, but only somewhat delayed; this underlines that IL-1 beta and 
HMGB1 do not utilize the some carrier molecules to traverse the membranes of secretory 
Iysosomes, and also that degranulation of these organelles is not affected. 
MRP transporters are described as gated, cylindrical, membrane embedded, 
hydrophilic pores (Rosenberg et al 1997), and HMGB 1, which has a bi-Iobar structure 
(Knapp et al 2004), must pass through them. I tried to give a mechanistic explanation of the 
process using a unfolding assay based on DHFR and MTX (Eilers and Schatz 1986), and I 
suggest that HMGB1 has to unfold its ternary and secondary structure during the 
translocation process (figure 28). 
Moreover, MRP1 and MRP2 have been known since the 80s as pumps that actively 
transport glutathionylated compounds (Leier et al 1994). I looked in vivo (figures 21 and 22) 
and in vitro (figure 24) for a possible glutathione modification of HMGB 1. I found that purified 
recombinant HMGB1 is highly reactive to reduced glutathione, and intracellular HMGB1 
appears modified by glutathione. Mutating the HMGB1 cysteine residues 44 and 105 blocks 
HMGB1 secretion (figure 26), which suggests that these are the GSH reactive sites. These 
findings suggest that MRPs can recognize HMGB1 for transport via its glutathione 
modification. 
The ability of MRPs to transport polypeptides is not completely new. In fact, other 
components of the ABC transporter superfamily are known to translocate antigenic peptides 
originated by proteasomal degradation, namely the ABCB2/ABCB3 heterodimer (TAP1ITAP2 
protein), which is expressed on the ER of phagocytic cells displaying MHC class I molecules 
(Vos et al 1999; 2000). MRP1 itself can transport small hydrophobic peptides (de Jong et al 
2001). I now show that a full length, functional protein can be recognised and transported by 
MRPs. 
52 
Discussion 
The link between HMGB 1 secretion and MRP1 throws some light on the mechanism 
of at least one non-classical transport pathway. In addition, it may have unexpected practical 
value in the management of cancer patients. I argue that MRP expressing tumour cells will 
secrete HMGB1 at a significant rate, with possible unfavourable consequences. Long-term 
tumour drug treatments could positively selects MRP expressing tumour cell clones. MRPs 
expression by tumour cells may give them positive fitness by permitting them to secrete 
HMGB1: via HMGB1 tumour cells may stimulate their own cell growth and induce 
angiogenesis to feed themselves (Zeh and Lotze 2005, Schlueter et al 2005). In this case 
targeting HMGB1 secretion might be highly relevant for subsets of drug resistant cancer 
patients, even more so than for cancer patients in general (Lotze and DeMarco 2003), as 
well as for patients with sepsis. 
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